Cryptorchidism Medical Services in China

Cryptorchidism, or undescended testis, is a common congenital urological condition in male infants where one or both testes fail to descend into the scrotum by six months of age. Prevalence ranges from 1–3% in full-term newborns and up to 30% in preterm infants. Untreated cryptorchidism increases long-term risks—including impaired spermatogenesis, testicular atrophy, infertility, and a three- to eight-fold elevated risk of testicular germ cell tumors. Early diagnosis via physical examination and ultrasound is essential; definitive management typically involves surgical orchidopexy between 6 and 18 months of age, with hormonal therapy reserved for select cases. Delayed intervention beyond two years correlates with irreversible germ cell loss and suboptimal fertility outcomes.

China offers distinct advantages for international patients seeking treatment: board-certified pediatric urologists and andrologists with extensive experience in microsurgical orchidopexy and laparoscopic techniques; widespread access to high-resolution ultrasound, intraoperative Doppler imaging, and robotic-assisted platforms; consistently high success rates (>95% anatomical correction with low complication incidence); and costs averaging 40–60% lower than those in the US, UK, or Germany—without compromising clinical standards. As a dedicated medical tourism agency, we facilitate seamless care pathways for global patients: vetting JCI-accredited hospitals, coordinating appointments with specialist teams, providing itemized, transparent pricing in advance, arranging visas and local logistics, and offering multilingual clinical support throughout diagnosis, surgery, and follow-up.

Treatment Options & Itemized Cost Breakdown for Cryptorchidism (Male Urology)

Non-Surgical / Conservative Management

*Indicated only for infants <6 months with palpable, retractile, or high-lying but reducible testes; not for true non-palpable or intra-abdominal cases.*

• •hCG Injection Therapy (3–5 doses over 2–3 weeks):

- Administration fee (per dose): $8–$12 - Total course (5 doses): $60–$170

• •Preoperative Labs & Exams (mandatory baseline):

- Scrotal ultrasound (bilateral): $35–$50 - Pediatric urology consultation: $25–$40

Surgical / Procedural Intervention

*Standard of care for persistent cryptorchidism beyond 6–12 months; includes inguinal orchidopexy (most common) and laparoscopic orchidopexy (for non-palpable testes).*

• •Inguinal Orchidopexy (open, unilateral):

- Preoperative workup (CBC, coagulation panel, ECG, chest X-ray): $95–$135 - Post-op follow-up (2 visits × $25): $50 - *Total estimated range*: $625–$905

• •Laparoscopic Orchidopexy (unilateral, intra-abdominal or impalpable testis):

- Preoperative workup (same as above): $95–$135 - *Total estimated range*: $945–$1,415

Special / Complex Condition Management

• •Bilateral Non-Palpable Testes: Requires diagnostic laparoscopy + possible staged orchidopexy or auto-transplantation: $1,650–$2,400
• •Vanishing Testis Syndrome (confirmed via laparoscopic biopsy): Surveillance only; biopsy cost included in laparoscopy: + $110–$160
• •Associated Hernia Repair (simultaneous inguinal hernia): Adds $220–$340 to base orchidopexy cost

Quick Selection Guide

• •Infant <6 months, palpable/retractile testis: Start with hCG therapy ($60–$170); re-evaluate at 6 months.
• •Child 6–12 months, unilateral palpable: Inguinal orchidopexy ($625–$905) — optimal balance of efficacy, safety, and cost.
• •Child >12 months or non-palpable testis: Laparoscopic orchidopexy ($945–$1,415) — gold standard for localization and fixation.
• •Bilateral intra-abdominal or complex anatomy: Staged laparoscopic approach ($1,650–$2,400) — prioritizes fertility preservation and hormonal function.
• •Budget-constrained families: Inguinal orchidopexy remains first-line; avoid delayed surgery (>18 months) due to irreversible germ cell loss risk.
• •Comorbidities (e.g., severe asthma, bleeding disorder): Preoperative pulmonology/hematology consult ($35–$55 each) required; may shift to open over laparoscopic if anesthesia risk elevated.